Small Pharma Inc. (DMTTF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Small Pharma Inc. (DMTTF) with AI Score 44/100 (Weak). Small Pharma Inc. is a biotechnology company focused on developing short-acting psychedelics for mental health conditions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Small Pharma Inc. (DMTTF) Healthcare & Pipeline Overview
Small Pharma Inc., a UK-based biotechnology firm, specializes in developing psychedelic-assisted therapies for mental health, with a focus on short-acting DMT treatments. Their lead program targets major depressive disorder, positioning them in the emerging market for innovative mental health solutions, but faces regulatory and clinical trial risks.
Investment Thesis
Small Pharma Inc. presents a high-risk, high-reward investment opportunity within the burgeoning psychedelic medicine sector. The company's focus on short-acting DMT therapies offers potential advantages in terms of patient convenience and therapeutic control. The Phase IIA clinical trial for SPL026 in major depressive disorder is a key value driver; positive results could significantly increase the company's valuation. However, the company's small market capitalization ($0.04B) and negative P/E ratio (-2.15) reflect the inherent risks associated with early-stage biotechnology companies. Successful navigation of regulatory hurdles and demonstration of clinical efficacy are critical for Small Pharma's long-term success.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.04 billion indicates a small-cap company with potential for high growth but also higher risk.
- Negative P/E ratio of -2.15 reflects the company's current lack of profitability, common for biotechnology firms in the development stage.
- Beta of 0.85 suggests the stock is less volatile than the overall market.
- Lead clinical program, SPL026, is in Phase IIA trials, representing a key milestone in the drug development process.
- Focus on short-acting DMT therapies differentiates Small Pharma from competitors developing longer-acting psychedelic treatments.
Competitors & Peers
Strengths
- Focus on short-acting DMT therapies offers potential advantages in terms of patient convenience and therapeutic control.
- Lead clinical program, SPL026, is in Phase IIA trials, representing a key milestone.
- Strong intellectual property portfolio protecting novel psychedelic compounds and therapeutic methods.
- Experienced management team with expertise in drug development and commercialization.
Weaknesses
- Small market capitalization and limited financial resources.
- Reliance on a single lead clinical program, SPL026.
- High regulatory hurdles and uncertainty surrounding the approval of psychedelic therapies.
- Limited commercialization experience.
Catalysts
- Upcoming: Release of Phase IIA clinical trial results for SPL026 in major depressive disorder (timeline: within the next 6-12 months).
- Upcoming: Initiation of Phase III clinical trials for SPL026, contingent on positive Phase IIA results (timeline: potentially within 1-2 years).
- Ongoing: Development and advancement of preclinical programs, including SPL028, SPL029, and SPL801.
- Ongoing: Potential for strategic partnerships with pharmaceutical companies or research institutions.
- Ongoing: Regulatory developments and changes in the legal status of psychedelic therapies.
Risks
- Potential: Failure to achieve positive results in clinical trials for SPL026 or other pipeline programs.
- Potential: Regulatory setbacks and delays in the approval process for psychedelic therapies.
- Potential: Competition from other biotechnology companies developing psychedelic therapies.
- Ongoing: Negative public perception of psychedelic drugs and potential for social stigma.
- Ongoing: Limited financial resources and potential need for additional funding.
Growth Opportunities
- Advancement of SPL026 through Clinical Trials: Successful completion of Phase IIA trials for SPL026 and progression to Phase III represents a significant growth opportunity. Positive clinical data could lead to regulatory approval and commercialization, addressing a substantial market for major depressive disorder treatments. The timeline for Phase III trials and potential market entry is estimated at 3-5 years, with a potential market size in the billions of dollars.
- Expansion of Preclinical Pipeline: The development of SPL028, SPL029, and SPL801 offers opportunities to diversify Small Pharma's product portfolio and address different aspects of psychedelic therapy. These preclinical programs could lead to novel treatments with improved efficacy, duration of action, or routes of administration. The timeline for these programs to reach clinical trials is estimated at 2-4 years.
- Strategic Partnerships and Collaborations: Forming partnerships with pharmaceutical companies, research institutions, or mental health clinics could accelerate the development and commercialization of Small Pharma's therapies. Collaborations can provide access to funding, expertise, and distribution channels, enhancing the company's competitive position. The potential impact of strategic partnerships is immediate and ongoing.
- Geographic Expansion: Expanding operations beyond the United Kingdom to other regions with favorable regulatory environments for psychedelic medicine, such as North America and Europe, represents a growth opportunity. Geographic expansion could increase the company's market reach and revenue potential. The timeline for geographic expansion is estimated at 1-3 years.
- Intellectual Property Protection: Securing and maintaining strong intellectual property protection for its psychedelic compounds and therapeutic methods is crucial for Small Pharma's long-term growth. Patents provide exclusivity and prevent competitors from replicating the company's innovations, creating a competitive advantage. The ongoing effort to strengthen and defend its IP portfolio is a continuous growth driver.
Opportunities
- Growing market for psychedelic medicine and increasing acceptance of psychedelic therapies.
- Potential for strategic partnerships with pharmaceutical companies and research institutions.
- Expansion of preclinical pipeline to address different aspects of psychedelic therapy.
- Geographic expansion to regions with favorable regulatory environments.
Threats
- Competition from other biotechnology companies developing psychedelic therapies.
- Regulatory setbacks and delays in the approval process.
- Negative public perception of psychedelic drugs.
- Patent challenges and intellectual property disputes.
Competitive Advantages
- Intellectual property protection for novel psychedelic compounds and therapeutic methods.
- Clinical data demonstrating the safety and efficacy of their therapies.
- Strategic partnerships with pharmaceutical companies and research institutions.
- First-mover advantage in the emerging market for short-acting DMT therapies.
About DMTTF
Small Pharma Inc. was founded in 2015 with the goal of pioneering short-acting psychedelic therapies for mental health disorders. The company's primary focus is on developing treatments using N,N-dimethyltryptamine (DMT), a potent psychedelic compound, in conjunction with psychotherapy. Their lead clinical program, SPL026, involves DMT-assisted therapy for major depressive disorder and is currently in Phase IIA clinical trials. Beyond SPL026, Small Pharma is also developing a pipeline of preclinical programs, including SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801, an oral formulation of 6-hydroxynorketamine. These programs aim to address various aspects of psychedelic therapy, such as duration of effect and route of administration. The company is headquartered in London, United Kingdom, and operates within the rapidly evolving landscape of psychedelic medicine, seeking to provide innovative solutions for unmet needs in mental healthcare. Small Pharma's strategy involves rigorous scientific research, clinical trials, and strategic partnerships to advance its pipeline and bring novel therapies to market.
What They Do
- Develop short-acting psychedelic therapies for mental health conditions.
- Conduct clinical trials to evaluate the safety and efficacy of DMT-assisted therapy.
- Research and develop novel psychedelic compounds and formulations.
- Seek regulatory approval for their therapies from health authorities.
- Commercialize approved therapies through partnerships or direct sales.
- Explore new applications of psychedelic medicine in mental healthcare.
Business Model
- Develop and patent novel psychedelic compounds and therapeutic methods.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from health authorities.
- Commercialize approved therapies through partnerships or direct sales.
Industry Context
Small Pharma Inc. operates within the rapidly expanding psychedelic medicine industry, which is gaining increasing attention for its potential to treat mental health disorders. The market is driven by a growing unmet need for effective treatments for conditions like depression, anxiety, and PTSD. Companies like Small Pharma are pioneering the development of psychedelic-assisted therapies, facing both regulatory hurdles and significant market opportunities. The competitive landscape includes other biotechnology firms exploring various psychedelic compounds and therapeutic approaches, creating a dynamic and evolving market environment.
Key Customers
- Patients suffering from mental health disorders, such as major depressive disorder.
- Mental health professionals who administer psychedelic-assisted therapy.
- Healthcare providers who prescribe or recommend Small Pharma's therapies.
- Pharmaceutical companies that may partner with Small Pharma for commercialization.
Financials
Chart & Info
Small Pharma Inc. (DMTTF) stock price: Price data unavailable
Latest News
No recent news available for DMTTF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DMTTF.
Price Targets
Wall Street price target analysis for DMTTF.
MoonshotScore
What does this score mean?
The MoonshotScore rates DMTTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: George Tziras
CEO
George Tziras is the CEO of Small Pharma Inc. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held leadership positions at various companies, where he was responsible for overseeing clinical trials, regulatory submissions, and market access strategies. Tziras has a strong understanding of the regulatory landscape for psychedelic medicine and is committed to bringing innovative therapies to patients in need.
Track Record: Under George Tziras's leadership, Small Pharma Inc. has advanced its lead clinical program, SPL026, into Phase IIA trials. He has also overseen the expansion of the company's preclinical pipeline and the strengthening of its intellectual property portfolio. Tziras has successfully raised capital to fund the company's research and development activities and has established strategic partnerships with key stakeholders in the psychedelic medicine industry.
DMTTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Small Pharma Inc. may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited or no financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Higher price volatility.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property portfolio.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Experienced management team with a track record in the pharmaceutical or biotechnology industry.
- Progress in clinical trials for SPL026 and other pipeline programs.
- Strong intellectual property portfolio protecting novel psychedelic compounds and therapeutic methods.
- Strategic partnerships with reputable research institutions or pharmaceutical companies.
- Positive media coverage and industry recognition.
What Investors Ask About Small Pharma Inc. (DMTTF)
What does Small Pharma Inc. do?
Small Pharma Inc. is a biotechnology company focused on developing short-acting psychedelic-assisted therapies for mental health conditions, primarily major depressive disorder. Their lead clinical program, SPL026, utilizes N,N-dimethyltryptamine (DMT) in conjunction with psychotherapy. The company aims to provide innovative and effective treatments for mental health disorders by leveraging the unique properties of DMT and other psychedelic compounds. Their business model involves research, clinical trials, regulatory approval, and eventual commercialization of these therapies.
What do analysts say about DMTTF stock?
As of March 18, 2026, formal analyst coverage of DMTTF is limited due to its small market capitalization and OTC listing. However, the general sentiment surrounding the psychedelic medicine sector is positive, with increasing recognition of the potential of psychedelic therapies to address unmet needs in mental healthcare. Investors should conduct their own due diligence and consider the inherent risks associated with early-stage biotechnology companies before investing in DMTTF. Key valuation metrics and growth considerations include the progress of SPL026 through clinical trials and the company's ability to secure regulatory approval.
What are the main risks for DMTTF?
The main risks for Small Pharma Inc. include the inherent uncertainties associated with drug development, such as the potential for clinical trial failures or regulatory setbacks. The company also faces competition from other biotechnology companies developing psychedelic therapies. Negative public perception of psychedelic drugs and potential for social stigma could also hinder the adoption of their therapies. Additionally, Small Pharma's limited financial resources and reliance on a single lead clinical program represent significant risks for investors.
What are the key factors to evaluate for DMTTF?
Small Pharma Inc. (DMTTF) currently holds an AI score of 44/100, indicating low score. Key strength: Focus on short-acting DMT therapies offers potential advantages in terms of patient convenience and therapeutic control.. Primary risk to monitor: Potential: Failure to achieve positive results in clinical trials for SPL026 or other pipeline programs.. This is not financial advice.
How frequently does DMTTF data refresh on this page?
DMTTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DMTTF's recent stock price performance?
Recent price movement in Small Pharma Inc. (DMTTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on short-acting DMT therapies offers potential advantages in terms of patient convenience and therapeutic control.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DMTTF overvalued or undervalued right now?
Determining whether Small Pharma Inc. (DMTTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DMTTF?
Before investing in Small Pharma Inc. (DMTTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 18, 2026.
- OTC market data may be limited or unreliable.
- Analyst coverage may be sparse due to the company's small market capitalization.